BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10588850
• 负责人: Victoria B Risbrough
• 金额: --
• 依托单位: VA SAN DIEGO HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-10-01 至 2027-09-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10588850
• 关键词: Acute; Adult; Alcohol consumption; Animal Model; Astrocytes; Award; Behavior; Behavioral; Biological Markers; Biological Psychiatry; CRF receptor type 1; CRF receptor type 2; California; Chronic; Clinical; Clinical Research; Clinical Trials; Cognitive; Collection; Communication; Corticotropin-Releasing Hormone; Country; Department of Defense; Development; Diagnosis; Diagnostic; Disease; Extinction; Fright; Functional disorder; Funding; Future; Genetic; Genetic Polymorphism; Genetic Risk; Health; Healthcare Systems; Hormones; Human; Immune system; Intervention; Journals; K-Series Research Career Programs; Laboratories; Laboratory Research; Learning; Liquid substance; Longevity; Maintenance; Manuscripts; Marines; Mental Health; Mentors; Mentorship; Molecular; Mus; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; Nature; Nerve Degeneration; Neurobiology; Neurons; Neurosciences; Neurosciences Research; Oxytocin; Pharmacological Treatment; Physiological; Post-Traumatic Stress Disorders; Principal Investigator; Proteins; Psychiatry; Psychopharmacology; Psychophysiology; Publications; Publishing; Receptor Gene; Recovery; Research; Research Personnel; Risk; Risk Marker; Role; Running; Scientist; Signal Transduction; Sleep; Specialist; Stress; Symptoms; System; Training; Trauma; Traumatic Brain Injury; Treatment outcome; United States National Institutes of Health; Universities; Veterans; Work; alcohol comorbidity; biobank; biological adaptation to stress; blood-based biomarker; career; cell type; combat; cytotoxicity; dopamine system; endogenous cannabinoid system; exosome; follow-up; frontier; functional disability; genetic risk factor; health science research; heart rate variability; improved; indexing; longitudinal, prospective study; marine; mild traumatic brain injury; neuropathology; neuropsychopharmacology; novel; pharmacologic; post-trauma; pre-clinical; pre-clinical research; professor; prognostic tool; programs; psychosocial; receptor function; resilience; response; specific biomarkers; standard care; success; therapy development; tool; translational research program

Dr. Risbrough runs a cross-species translational research program to study mechanisms of trauma disorders including posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI). Her overall program aims to support development of novel treatments and diagnostic/prognostic tools for Veterans with PTSD and TBI. Dr. Risbrough focuses her preclinical research program on identifying mechanisms of risk and identifying potential novel treatments for PTSD using genetic, molecular and pharmacological tools in mice. She is known for her expertise in animal models of PTSD and the neurobiology of stress systems. Her current preclinical work includes identifying genetic risk markers for fear learning and extinction, identifying sleep and immune-system contributors to risk for PTSD and comorbid alcohol drinking and identifying novel treatments targeting dopamine and endocannabinoid systems to enhance fear-extinction based therapies. Her clinical research program includes identifying psychosocial, physiological and blood-based biomarkers of PTSD and TBI aimed at understanding mechanisms that impede recovery and induce functional impairment to improve intervention development. This program includes managing the San Diego VA Sleep Research Laboratory, the Psychophysiology Laboratory for the VA Center of Excellence for Stress and Mental Health (CESAMH), longitudinal PTSD/TBI Biorepository for CESAMH as well as her continued work as a Principal Investigator for the Marine Resiliency Study, a prospective longitudinal study of OIF/OEF Marines now in its 10 year follow up collection period. Finally, she also conducts clinical studies to identify novel pharmacological treatments for PTSD. Her research program is funded by NIMH, NIAAA, Department of Defense in addition to VA BLR&D and VA Center of Excellence for Stress and Mental Health funds.

Risbrough博士开展了一项跨物种转化研究计划，研究 创伤性障碍，包括创伤后应激障碍（PTSD）和创伤性脑损伤 （TBI）。她的整体计划旨在支持开发新的治疗方法， 创伤后应激障碍和创伤性脑损伤退伍军人的诊断/预后工具。里斯布罗医生让她 临床前研究计划，以确定风险机制和确定潜在的新 在小鼠中使用遗传、分子和药理学工具治疗PTSD。大家都知道她 她在创伤后应激障碍动物模型和应激系统神经生物学方面的专业知识。她现在的 临床前工作包括鉴定恐惧学习和灭绝的遗传风险标记， 确定睡眠和免疫系统对PTSD和共病酒精风险的贡献 饮用并确定针对多巴胺和内源性大麻素系统的新疗法， 加强基于消除恐惧的疗法。她的临床研究项目包括识别 PTSD和TBI的心理社会、生理和血液生物标志物， 了解阻碍恢复和诱导功能障碍的机制，以改善 干预发展。该计划包括管理圣地亚哥VA睡眠研究 实验室，心理生理学实验室的VA卓越中心的压力和 心理健康（CESAMH），CESAMH的纵向PTSD/TBI生物储存库以及她的 继续作为海洋复原力研究的主要研究员工作，这是一项前瞻性的研究。 OIF/OEF海军陆战队的纵向研究现在处于10年的随访收集期。最后， 她还进行临床研究，以确定新的药物治疗创伤后应激障碍。她 该研究计划由美国国家医学和卫生研究所、美国国家航空航天局、国防部以及美国退伍军人事务部研究与发展中心共同资助 和退伍军人管理局压力和心理健康卓越中心基金。